[Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome].
OBJECTIVE
To observe the effect of simvastatin on expression of CX3CR1 in the monocytes in patients with acute coronary syndrome and investigate the non-lipid mechanisms of statins against atherosclerosis.


METHODS
The expression of CX3CR1 in the monocytes was measured by quantitative real-time RT-PCR in 63 patients with acute coronary syndrome confirmed by coronary arteriography after treatment with simvastatin at 10(-7) approximately 10(-5) mol/L for 4, 8 and 12 h, respectively.


RESULTS
CX3CR1 expression in the monocytes treated with different concentrations of simvastatin was significantly lower than that in the control cells (P<0.05), and the expression in the cells treated with the agent for different time lengths was also significantly lower than that in the control cells (P<0.01).


CONCLUSIONS
Simvastatin can reduce CX3CR1 expression in the monocytes of the patients with acute coronary syndrome in a concentration- and time-dependent manner, so as to reduce the inflammation and stabilize the vascular plaques.
Peng
Dan-dan
DD
Department of Cardiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. pdd009@126.com
Li
Zhi-liang
ZL
D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy*; D000073883:CX3C Chemokine Receptor 1; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D019707:Receptors, Chemokine / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019821:Simvastatin / Q000627:therapeutic use*
D000073883:CX3C Chemokine Receptor 1; C095235:CX3CR1 protein, human; D000960:Hypolipidemic Agents; D019707:Receptors, Chemokine; D019821:Simvastatin